These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 26293331)

  • 1. Preventive Strategies for Patients at Risk of Medication-related Osteonecrosis of the Jaw.
    Goodday RH
    Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):527-36. PubMed ID: 26293331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiresorptives and osteonecrosis of the jaw.
    Yamashita J; McCauley LK
    J Evid Based Dent Pract; 2012 Sep; 12(3 Suppl):233-47. PubMed ID: 23040351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiresorptive treatment-associated ONJ.
    Eleutherakis-Papaiakovou E; Bamias A
    Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 29063702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw.
    Khan AA; Sándor GK; Dore E; Morrison AD; Alsahli M; Amin F; Peters E; Hanley DA; Chaudry SR; Dempster DW; Glorieux FH; Neville AJ; Talwar RM; Clokie CM; Al Mardini M; Paul T; Khosla S; Josse RG; Sutherland S; Lam DK; Carmichael RP; Blanas N; Kendler D; Petak S; St-Marie LG; Brown J; Evans AW; Rios L; Compston JE;
    J Rheumatol; 2008 Jul; 35(7):1391-7. PubMed ID: 18528958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates.
    DE Iuliis F; Taglieri L; Amoroso L; Vendittozzi S; Blasi L; Salerno G; Lanza R; Scarpa S
    Anticancer Res; 2014 May; 34(5):2477-80. PubMed ID: 24778063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Bisphosphonate and osteonecrosis of the jaw.].
    Taguchi A
    Clin Calcium; 2017; 27(2):225-231. PubMed ID: 28123124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Bisphosphonate-related osteonecrosis of the jaw].
    Atanes-Bonome P; Atanes-Bonome A; Ríos-Lage P; Atanes-Sandoval AD
    Semergen; 2014 Apr; 40(3):143-8. PubMed ID: 24001573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Position paper on medication-related osteonecrosis of the jaw (MRONJ)].
    Svejda B; Muschitz Ch; Gruber R; Brandtner Ch; Svejda Ch; Gasser RW; Santler G; Dimai HP
    Wien Med Wochenschr; 2016 Feb; 166(1-2):68-74. PubMed ID: 26847441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiresorptive Agent-Related Osteonecrosis of the Jaw (ARONJ): A Twist of Fate in the Bone.
    Shibahara T
    Tohoku J Exp Med; 2019 Feb; 247(2):75-86. PubMed ID: 30713280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Frequency of Medication-related Osteonecrosis of the Jaw and its Associated Risk Factors.
    Dodson TB
    Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):509-16. PubMed ID: 26362367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Osteonecrosis of the jaws (ONJ) associated to antiresorptive treatment].
    Larsson Wexell C; Kjellman A; Akre O
    Lakartidningen; 2018 May; 115():. PubMed ID: 29809272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
    Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
    Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug-induced osteonecrosis of the jaw: the state of the art.
    Fassio A; Bertoldo F; Idolazzi L; Viapiana O; Rossini M; Gatti D
    Reumatismo; 2017 May; 69(1):9-15. PubMed ID: 28535616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiresorptive drug-related osteonecrosis of the jaw.
    Uyanne J; Calhoun CC; Le AD
    Dent Clin North Am; 2014 Apr; 58(2):369-84. PubMed ID: 24655528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral bisphosphonates as a cause of bisphosphonate-related osteonecrosis of the jaws: clinical findings, assessment of risks, and preventive strategies.
    Assael LA
    J Oral Maxillofac Surg; 2009 May; 67(5 Suppl):35-43. PubMed ID: 19371813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of osteoclast modifiers on the oral cavity: a review for prescribers.
    Epstein MS; Epstein JB; Ephros HD
    Curr Opin Support Palliat Care; 2012 Sep; 6(3):337-41. PubMed ID: 22871978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Preserving the oral health of patients on antiresorptive drugs].
    Tilotta F; Folliguet M; Radoï L
    Rev Prat; 2023 Apr; 73(4):421-429. PubMed ID: 37289162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteonecrosis of the jaw in patients receiving intravenous or oral bisphosphonates.
    King AE; Umland EM
    Pharmacotherapy; 2008 May; 28(5):667-77. PubMed ID: 18447663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Bisphosphonate-related osteonecrosis of the jaw].
    Franken AA; van Blijderveen NJ; Witjes MJ; Netelenbos CJ
    Ned Tijdschr Geneeskd; 2011; 155():A3077. PubMed ID: 21486510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenetics of Bisphosphonate-associated Osteonecrosis of the Jaw.
    Fung PL; Nicoletti P; Shen Y; Porter S; Fedele S
    Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):537-46. PubMed ID: 26299425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.